NDATOPICALCREAMPriority Review
Approved
Aug 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HALOTEX (haloprogin) is a topical antifungal cream approved in 1971 for dermatological fungal infections. The drug is a small-molecule antifungal agent applied directly to affected skin areas. It represents an older generation of topical antifungal therapy with limited modern clinical activity.
LOE Approaching
With LOE approaching and minimal linked job activity, commercial teams supporting HALOTEX are likely in maintenance mode with minimal headcount expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job postings and LOE approaching, HALOTEX represents a declining career opportunity within Bristol Myers Squibb's dermatology portfolio. Professionals supporting this product should anticipate portfolio transition or reassignment as the brand moves toward post-LOE maintenance.
Brand ManagerField Sales Representative
Worked on HALOTEX at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.